In This Article:
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on the shares. The Q4 updates, which included “favorable” two-year OLE data, were “positive” and Rezdiffra’s launch has been “robust” despite the firm’s initial concerns, the analyst tells investors. However, while the firm recognizes room for further near-term sales upside, the extent to which this has already been priced into shares and the “aggressive expansion” of 2025 and later forecasts are “concerning,” adds the analyst, who sees increasing downside risks despite Madrigal’s successes.
Discover the Best Stocks and Maximize Your Portfolio:
-
See what stocks are receiving Strong Buy ratings from top-rated analysts.
-
Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
-
Nvidia, Constellation Brands downgraded: Wall Street’s top analyst calls
-
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley
-
Madrigal Pharmaceuticals price target raised to $443 from $427 at Citizens JMP
-
Madrigal Pharmaceuticals price target raised to $475 from $400 at Oppenheimer
-
Madrigal Pharmaceuticals price target raised to $469 from $378 at Citi